← Back to Search

Peptide Dimer

KSP/QRH dimer for Barrett's Esophagus

Phase 1
Waitlist Available
Led By Danielle K Turgeon, MD
Research Sponsored by University of Michigan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Has known or suspected Barrett's esophagus
Willing and able to sign informed consent
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during and immediately after procedure, generally no more than 2 hours
Awards & highlights

Study Summary

This trial is looking at using a new imaging agent, a fluorescent-labeled peptide dimer, to help guide endoscopic biopsy or endoscopic mucosal resection (EMR) for patients with Barrett's esophagus.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during and immediately after procedure, generally no more than 2 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and during and immediately after procedure, generally no more than 2 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Binding of KSP/QRH dimer to EGFR and HER2
SFE ability to detect dimer by SNR
SFE ability to detect dimer by fluorescence T/B ratio
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Esophagus sprayed with KSP/QRH dimerExperimental Treatment1 Intervention
Area of interest in subject's esophagus sprayed with KSP/QRH dimer and imaged with the SFE probe

Find a Location

Who is running the clinical trial?

University of MichiganLead Sponsor
1,785 Previous Clinical Trials
6,364,792 Total Patients Enrolled
Danielle K Turgeon, MDPrincipal InvestigatorUniversity of Michigan

Frequently Asked Questions

~7 spots leftby Mar 2025